EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of TPH2 polymorphisms with valproic acid efficacy and neurological adverse events in pediatric epilepsy

Jiahao Zhu, Xixuan Wang, Xianhuan Shen, Hanbing Xia, Yaodong He, Qian Liu, Jianping Zhang, Xiaomei Fan, Wenzhou Li

Frontiers in Pharmacology · 13.07.2026 · 17

DOI: 10.3389/fphar.2026.1821776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.07.2026. Verfasst von Jiahao Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, China. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Valproic acid (VPA) response in pediatric epilepsy shows high variability. This study investigated the association of tryptophan hydroxylase-2 ( TPH2 ) polymorphisms with VPA efficacy and adverse drug reactions (ADRs) in children.

Methods

In a retrospective cohort of 199 children with epilepsy receiving VPA treatment, TPH2 rs4570625 and rs1386494 were genotyped using Sequenom MassArray. Efficacy was categorized as uncontrolled seizure vs. seizure-free. ADRs were systemically recorded, and steady-state VPA concentrations were measured. Network pharmacology integrated protein-protein interactions, and functional enrichment to elucidate TPH2 ’s role in VPA-related neurotoxicity.

Results

The rs4570625 polymorphism was significantly associated with VPA treatment outcomes. GG homozygotes exhibited higher seizure-free rates ( p = 0.031) and lower incidence of neurological ADRs ( p = 0.036). GG carriers also displayed significantly higher VPA serum concentrations. Network pharmacology analyses identified the serotonergic synapse as the dominant enriched pathway linking TPH2 to VPA neurotoxicity, with MAOA and SLC6A4 as key regulatory hubs. No significant associations were observed between rs1386494 polymorphism and VPA treatment outcomes.

Conclusion

TPH2 rs4570625 may serve as a potential exploratory biomarker for predicting VPA efficacy and neurological toxicity in pediatric epilepsy, mediated through serotonergic pathway dysregulation. Genotype-guided personalization could optimize VPA therapy.

Schlagwörter

Stichwörter der Autor:innen

TPH2adverse drug reactionchildhood epilepsypolymorphismresponsivenessvalproic acid

Autor:innen und Institutionen

  • Department of Pharmacy, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, China.
  • Department of Clinical Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.

Zitieren

APA

Zhu, J., Wang, X., Shen, X., Xia, H., He, Y., Liu, Q., Zhang, J., Fan, X., & Li, W. (2026). Association of TPH2 polymorphisms with valproic acid efficacy and neurological adverse events in pediatric epilepsy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1821776

Vancouver

Zhu J, Wang X, Shen X, Xia H, He Y, Liu Q, et al. Association of TPH2 polymorphisms with valproic acid efficacy and neurological adverse events in pediatric epilepsy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1821776

BibTeX
@article{Zhu2026,
  author = {Zhu, Jiahao and Wang, Xixuan and Shen, Xianhuan and Xia, Hanbing and He, Yaodong and Liu, Qian and Zhang, Jianping and Fan, Xiaomei and Li, Wenzhou},
  title = {Association of TPH2 polymorphisms with valproic acid efficacy and neurological adverse events in pediatric epilepsy},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1821776}
}
Kostenlos starten →